Home LiteratureArticle Details
PMID: 16541101 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Endocrine functions of bile acids.

The EMBO journal ·Vol. 25 ·No. 7 ·2006-04-05 ·Pages 1419-25

Houten SM, Watanabe M, Auwerx J

Abstract

Bile acids (BAs), a group of structurally diverse molecules that are primarily synthesized in the liver from cholesterol, are the chief components of bile. Besides their well-established roles in dietary lipid absorption and cholesterol homeostasis, it has recently emerged that BAs are also signaling molecules, with systemic endocrine functions. BAs activate mitogen-activated protein kinase pathways, are ligands for the G-protein-coupled receptor TGR5, and activate nuclear hormone receptors such as farnesoid X receptor alpha. Through activation of these diverse signaling pathways, BAs can regulate their own enterohepatic circulation, but also triglyceride, cholesterol, energy, and glucose homeostasis. Thus, BA-controlled signaling pathways are promising novel drug targets to treat common metabolic diseases, such as obesity, type II diabetes, hyperlipidemia, and atherosclerosis.

MeSH Terms
Animals Bile Acids and Salts/physiology Cholesterol/metabolism DNA-Binding Proteins/metabolism Endocrine System/physiology Energy Metabolism Enzyme Activation Glucose/metabolism Homeostasis Humans Ligands Lipid Metabolism Liver/metabolism MAP Kinase Signaling System/physiology Receptors, Cytoplasmic and Nuclear Receptors, G-Protein-Coupled/metabolism Signal Transduction Transcription Factors/metabolism
Chemicals
Bile Acids and Salts DNA-Binding Proteins GPBAR1 protein, human Ligands Receptors, Cytoplasmic and Nuclear Receptors, G-Protein-Coupled Transcription Factors farnesoid X-activated receptor Cholesterol Glucose
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Houten Sander M
Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands.
Watanabe Mitsuhiro
Auwerx Johan
References (69)
69 references, click to expand
  1. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.
    JAMA. 2003 Aug 13;290(6):765-72 PMID: 12915429
  2. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle.
    J Biol Chem. 2003 Oct 3;278(40):39124-32 PMID: 12865425
  3. The enzymes, regulation, and genetics of bile acid synthesis.
    Annu Rev Biochem. 2003;72:137-74 PMID: 12543708
  4. Mitochondrial dysfunction and type 2 diabetes.
    Science. 2005 Jan 21;307(5708):384-7 PMID: 15662004
  5. Regulation of carbohydrate metabolism by the farnesoid X receptor.
    Endocrinology. 2005 Mar;146(3):984-91 PMID: 15564327
  6. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1.
    Biochem Biophys Res Commun. 2005 Apr 1;329(1):386-90 PMID: 15721318
  7. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition.
    J Biol Chem. 2005 Aug 19;280(33):29971-9 PMID: 15899888
  8. Farnesoid X receptor: from structure to potential clinical applications.
    J Med Chem. 2005 Aug 25;48(17):5383-403 PMID: 16107136
  9. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
    Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2020-30 PMID: 16037564
  10. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.
    Cell Metab. 2005 Oct;2(4):217-25 PMID: 16213224
  11. The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes.
    Cell Metab. 2005 Oct;2(4):227-38 PMID: 16213225
  12. Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.
    J Med Chem. 2005 Nov 3;48(22):6948-55 PMID: 16250653
  13. FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine.
    J Lipid Res. 2006 Jan;47(1):201-14 PMID: 16251721
  14. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.
    Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11 PMID: 16410358
  15. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
    Nature. 2006 Jan 26;439(7075):484-9 PMID: 16400329
  16. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis.
    Genes Dev. 2003 Jul 1;17(13):1581-91 PMID: 12815072
  17. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes.
    Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13656-61 PMID: 10570128
  18. Identification of a chemical tool for the orphan nuclear receptor FXR.
    J Med Chem. 2000 Aug 10;43(16):2971-4 PMID: 10956205
  19. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors.
    Mol Cell. 2000 Sep;6(3):507-15 PMID: 11030331
  20. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.
    Mol Cell. 2000 Sep;6(3):517-26 PMID: 11030332
  21. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.
    Cell. 2000 Sep 15;102(6):731-44 PMID: 11030617
  22. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta.
    Genes Dev. 2000 Nov 15;14(22):2819-30 PMID: 11090130
  23. Role of LXRs in control of lipogenesis.
    Genes Dev. 2000 Nov 15;14(22):2831-8 PMID: 11090131
  24. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity.
    Mol Endocrinol. 2002 Sep;16(9):2065-76 PMID: 12198243
  25. Bile acid regulation of gene expression: roles of nuclear hormone receptors.
    Endocr Rev. 2002 Aug;23(4):443-63 PMID: 12202460
  26. Identification of membrane-type receptor for bile acids (M-BAR).
    Biochem Biophys Res Commun. 2002 Nov 15;298(5):714-9 PMID: 12419312
  27. Nuclear receptors and the control of metabolism.
    Annu Rev Physiol. 2003;65:261-311 PMID: 12518001
  28. Identification of gene-selective modulators of the bile acid receptor FXR.
    J Biol Chem. 2003 Feb 28;278(9):7027-33 PMID: 12496277
  29. A G protein-coupled receptor responsive to bile acids.
    J Biol Chem. 2003 Mar 14;278(11):9435-40 PMID: 12524422
  30. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump.
    J Biol Chem. 2003 Mar 21;278(12):10214-20 PMID: 12525500
  31. Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes.
    Mol Cell Biol. 2003 May;23(9):3052-66 PMID: 12697808
  32. Genetic variation in the small heterodimer partner gene and young-onset type 2 diabetes, obesity, and birth weight in U.K. subjects.
    Diabetes. 2003 May;52(5):1276-9 PMID: 12716764
  33. Contribution of variants in the small heterodimer partner gene to birthweight, adiposity, and insulin levels: mutational analysis and association studies in multiple populations.
    Diabetes. 2003 May;52(5):1288-91 PMID: 12716767
  34. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.
    Mol Cell. 2003 Apr;11(4):1079-92 PMID: 12718892
  35. Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects.
    Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):575-80 PMID: 11136233
  36. Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway.
    J Biol Chem. 2001 May 11;276(19):15816-22 PMID: 11278771
  37. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.
    Mol Endocrinol. 2001 Oct;15(10):1720-8 PMID: 11579204
  38. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity.
    Endocrinology. 2002 May;143(5):1741-7 PMID: 11956156
  39. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.
    J Clin Invest. 2002 May;109(9):1125-31 PMID: 11994399
  40. A natural product that lowers cholesterol as an antagonist ligand for FXR.
    Science. 2002 May 31;296(5573):1703-6 PMID: 11988537
  41. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis.
    Dev Cell. 2002 Jun;2(6):713-20 PMID: 12062084
  42. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.
    J Clin Invest. 2003 Dec;112(11):1678-87 PMID: 14623915
  43. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR.
    Genes Dev. 2004 Jan 15;18(2):157-69 PMID: 14729567
  44. Glucose regulates the expression of the farnesoid X receptor in liver.
    Diabetes. 2004 Apr;53(4):890-8 PMID: 15047603
  45. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3.
    Nat Med. 2004 May;10(5):530-4 PMID: 15107844
  46. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.
    J Clin Invest. 2004 May;113(10):1408-18 PMID: 15146238
  47. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1.
    J Biol Chem. 2004 May 28;279(22):23158-65 PMID: 15047713
  48. The nuclear bile acid receptor FXR is activated by PGC-1alpha in a ligand-dependent manner.
    Biochem J. 2004 Sep 15;382(Pt 3):913-21 PMID: 15202934
  49. The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts.
    Ann Med. 2004;36(7):482-91 PMID: 15513299
  50. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism.
    J Lab Clin Med. 1971 Jul;78(1):94-121 PMID: 5569253
  51. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia.
    Lancet. 1974 Oct 19;2(7886):929-31 PMID: 4138590
  52. Changes in plasma triglyceride metabolism during withdrawal of bile.
    Metabolism. 1976 Nov;25(11):1259-68 PMID: 185488
  53. Circadian distribution of bile acid in the enterohepatic circulatory system in hamsters.
    J Lipid Res. 1976 Nov;17(6):600-4 PMID: 993671
  54. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia.
    J Lipid Res. 1978 Nov;19(8):1017-24 PMID: 731123
  55. Within-day fluctuations in serum bile-acid concentrations among normal control subjects and patients with hepatic disease.
    Am J Clin Pathol. 1980 Feb;73(2):196-201 PMID: 7188830
  56. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety.
    Ann Intern Med. 1981 Sep;95(3):257-82 PMID: 7023307
  57. Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones.
    Scand J Gastroenterol. 1982 Aug;17(5):587-92 PMID: 7178821
  58. Steady-state kinetics of serum bile acids in healthy human subjects: single and dual isotope techniques using stable isotopes and mass spectrometry.
    J Lipid Res. 1987 Mar;28(3):238-52 PMID: 3553403
  59. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial.
    Ann Intern Med. 1994 Sep 15;121(6):416-22 PMID: 8053615
  60. Identification of a nuclear receptor that is activated by farnesol metabolites.
    Cell. 1995 Jun 2;81(5):687-93 PMID: 7774010
  61. Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease.
    Am J Physiol. 1997 Jul;273(1 Pt 1):E37-45 PMID: 9252477
  62. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose.
    Mol Cell Biol. 1999 May;19(5):3760-8 PMID: 10207099
  63. Identification of a nuclear receptor for bile acids.
    Science. 1999 May 21;284(5418):1362-5 PMID: 10334992
  64. Bile acids: natural ligands for an orphan nuclear receptor.
    Science. 1999 May 21;284(5418):1365-8 PMID: 10334993
  65. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.
    Mol Cell. 1999 May;3(5):543-53 PMID: 10360171
  66. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model.
    Nat Med. 2004 Dec;10(12):1352-8 PMID: 15558057
  67. Ligand-dependent coactivation of the human bile acid receptor FXR by the peroxisome proliferator-activated receptor gamma coactivator-1alpha.
    J Pharmacol Exp Ther. 2005 Jan;312(1):170-8 PMID: 15329387
  68. Redundant pathways for negative feedback regulation of bile acid production.
    Dev Cell. 2002 Jun;2(6):721-31 PMID: 12062085
  69. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor.
    Mol Endocrinol. 2002 Jul;16(7):1590-7 PMID: 12089353
Article Info
Journal
The EMBO journal
Abbr.
EMBO J
ISSN
0261-4189
Published
2006-04-05
Epub
2006-00-16
Pages
1419-25
Language
English
Region
England
NLM ID
8208664
PMCID
PMC1440314
Subset
IM
Grants
NIDDK NIH HHS · P01 DK059820 · United States
NIDDK NIH HHS · R01 DK067320 · United States
NIDDK NIH HHS · DK067320 · United States
NIDDK NIH HHS · DK59820 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com